PureTech Announces Voluntary Delisting Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Source: seekingalpha
- Financial Update: As of December 31, 2025, PureTech reported consolidated cash, cash equivalents, and short-term investments totaling $277.3 million, which decreased to $248.1 million by March 31, 2026, indicating a decline in liquidity that may impact future investment capabilities.
- Delisting Notification: PureTech has notified Nasdaq of its intention to voluntarily delist, which means the company will no longer trade on the U.S. market, potentially raising concerns among investors regarding liquidity and market visibility, thereby affecting shareholder confidence.
- Change of Trading Venue: Despite the delisting from Nasdaq, PureTech's ordinary shares will continue to be listed on the London Stock Exchange, indicating a strategic shift towards the European market, which may better serve its primary investor base.
- IPO Developments: Concurrently, PureTech's neuropsychiatric drug development subsidiary, Seaport, has filed for a U.S. IPO, which could provide new funding sources for the company, although the overall market environment remains uncertain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
